Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 1, 2011, Pages 64-76

  Kleiman, Robin J ^a   Kimmel, Lida H ^a   Bove, Susan E ^a   Lanz, Thomas A ^a   Harms, John F ^a   Romegialli, Alison ^a   Miller, Kenneth S ^a   Willis, Amy ^a   Des Etages, Shelley ^a   Kuhn, Max ^a   Schmidt, Christopher J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 PYRIDIN 4 YL 1 (2,2,2 TRIFLUORO ETHYL 1H PYRAZOL 3 YL) PHENOXYMETHYL] QUINOLINE SUCCINIC ACID; CHOLINE ACETYLTRANSFERASE; CRE RECOMBINASE; DIACYLGLYCEROL ACYLTRANSFERASE; ENZYME INHIBITOR; FOLLISTATIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; HISTONE DEACETYLACE 4; HISTONE H3; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTRANSMITTER; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE I; PHOSPHODIESTERASE IC; POTASSIUM CHANNEL KV1.6; PRODYNORPHIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN; SYNAPTOTAGMIN 10; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUNTINGTON CHOREA; MOUSE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRAZOLES; QUINOLINES; SIGNAL TRANSDUCTION;

EID: 78650779872     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173294     Document Type: Article

References (41)

1. Arthur JS (2008) MSK activation and physiological roles. Front Biosci 13:5866-5879.
2. Baillie GS, Scott JD, and Houslay MD (2005) Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579:3264-3270.
3. Bates G (2009) In vivo validation of HDACs as therapeutic targets for HD, in 4th Annual Huntington's Disease Therapeutics Conference: A Forum for Drug Discovery and Development; 2009 April 27-30; Cannes, France. CHDI Foundation, Los Angeles, CA.
4. Benjamini Y and Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289-300.
5. Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Hervé D, Valjent E, and Girault JA (2008) Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28:5671-5685.
6. Bertran-Gonzalez J, Håkansson K, Borgkvist A, Irinopoulou T, Brami-Cherrier K, Usiello A, Greengard P, Hervé D, Girault JA, Valjent E, et al. (2009) Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. Neuropsychopharmacology 34:1710-1720.
7. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54:1205-1213.
8. Deak M, Clifton AD, Lucocq LM, and Alessi DR (1998) Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 17:4426-4441.
9. De Cesare D and Sassone-Corsi P (2000) Transcriptional regulation by cyclic AMP-responsive factors. Prog Nucleic Acid Res Mol Biol 64:343-369.
10. Doyle JP, Dougherty JD, Heiman M, Schmidt EF, Stevens TR, Ma G, Bupp S, Shrestha P, Shah RD, Doughty ML, et al. (2008) Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 135:749-762.
11. Duncan CE, Chetcuti AF, and Schofield PR (2008) Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. Psychiatr Genet 18:226-239.
12. Freudenreich CH and Lahiri M (2004) Structure-forming CAG/CTG repeat sequences are sensitive to breakage in the absence of Mrc1 checkpoint function and S-phase checkpoint signaling: implications for trinucleotide repeat expansion diseases. Cell Cycle 3:1370-1374.
13. Giampà C, DeMarch Z, D'Angelo V, Morello M, Martorana A, Sancesario G, Bernardi G, and Fusco FR (2006) Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease. Eur J Neurosci 23:11-20.
14. Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, and Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS ONE 5:e13417.
15. Giampà C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS, and Fusco FR (2009) Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol Dis 34:450-456.
16. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, et al. (2009) PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574-590.
17. Hebb AL, Robertson HA, and Denovan-Wright EM (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967-981.
18. Heffron D and Mandell JW (2005) Differential localization of MAPK-activated protein kinases RSK1 and MSK1 in mouse brain. Brain Res Mol Brain Res 136:134-141.
19. Hu H, McCaw EA, Hebb AL, Gomez GT, and Denovan-Wright EM (2004) Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20:3351-3363.
20. Hughes PE, Alexi T, Williams CE, Clark RG, and Gluckman PD (1999) Administration of recombinant human activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Neuroscience 92:197-209.
21. Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, and Omori K (2004) Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem 279:4366-4375.
22. Lahiri M, Gustafson TL, Majors ER, and Freudenreich CH (2004) Expanded CAG repeats activate the DNA damage checkpoint pathway. Mol Cell 15:287-293.
23. Laprade N and Soghomonian JJ (1995) Differential regulation of mRNA levels encoding for the two isoforms of glutamate decarboxylase (GAD65 and GAD67) by dopamine receptors in the rat striatum. Brain Res Mol Brain Res 34:65-74.
24. MacDonald ML, Eaton ME, Dudman JT, and Konradi C (2005) Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 57:1041-1051.
25. McCoy CE, Campbell DG, Deak M, Bloomberg GB, and Arthur JS (2005) MSK1 activity is controlled by multiple phosphorylation sites. Biochem J 387:507-517.
26. Morris BJ, Höllt V, and Herz A (1988) Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists. Neuroscience 25:525-532.
27. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460-10471.
28. Patterson KI, Brummer T, O'Brien PM, and Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475-489.
29. Roze E, Betuing S, Deyts C, Marcon E, Brami-Cherrier K, Pagès C, Humbert S, Mérienne K, and Caboche J (2008) Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J 22:1083-1093.
30. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, et al. (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690.
31. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126.
32. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, and Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396.
33. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, et al. (2006b) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374-385.
34. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, and Thompson LM (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97:6763-6768.
35. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, et al. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 105:15564-15569.
36. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, and West AR (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328:785-795.
37. Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, and Cederbaum SD (1996) Cloning and characterization of the human type II arginase gene. Genomics 38:118-123.
38. West AR and Grace AA (2004) The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 24:1924-1935.
39. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, and Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139:597-607.
40. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolsheimer E, Jacobsen E, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 102:4459-4464.
41. Zink M, Schmitt A, May B, Müller B, Demirakca T, Braus DF, and Henn FA (2004) Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res 66:151-157. (Pubitemid 38041113)